Advertisement: Birketts mid banner
Advertisement: cofinitive mid banner
Advertisement: Allia mid banner
Advertisement: Bar Ellison mid banner property
Advertisement: Featurespace mid banner
Advertisement: Ilux mid banner
Advertisement: Evelyn mid banner
Advertisement: Arm mid banner
Advertisement: CambridgeTechPodcast midbanner
Advertisement: Cambridge Network mid banner
Cambridgeand mid banner advertisement
Advertisement: Wild Knight Vodka
Advertisement: Alan Boswell Group mid banner
Advertisement: SATAVIA mid banner
Advertisement mid banner S-Tech 3
Advertisement: Mogrify mid banner
Barr Ellison Solicitors – commercial property
Advertisement: TTP
Advertisement: CJBS mid banner
Advertisement: SJIP Dirac Building mid-banner
Advertisement: RSM mid banner
Advertisement: Shearline mid banner
Mid banner advertisement: BDO
Advertisement: Simpsons Creative mid banner
Advertisement: SourceBioscience mid banner
Advertisement: Bicycle mid banner
Advertisement: Marshall mid banner
16 October, 2023 - 10:22 By Tony Quested

US surge sends Tristel soaring to unprecedented heights

Tristel reports the strongest outlook in its 30-year history – driven by key North American regulatory approvals for its infection control products for hospitals.

The stock was 20p – more than five per cent – ahead to 415p a share soon after the UK market opened to read Tristel’s audited preliminary results for the year to June 30.

Turnover was up 16 per cent to £36 million; overseas sales continued to grow – up 17 per cent to £23.5m and represented 65 per cent of total sales. Pre-tax profit more than trebled to £5.1m (2022: £1.6m).

Dividend per share was hoisted 10 per cent to 10.50p and cash was fractionally higher at £9.5m with continued strong operating cashflow of £8.4m in the year (£5.6m).

The company sells hospitals its proprietary chlorine dioxide chemistry for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand.

Chief executive Paul Swinney said: “The enormous achievement of the year has been the FDA approval, which enables us to enter the largest healthcare market in the world. 

“We will also be able to leverage the significance of an FDA approval in countries that look to the USA regulator for their own practice. This includes Central and South America. We now have the opportunity to establish a global footprint for our products and technology.

“We have commenced manufacture and shipped product to our first customers in the US.  The outlook for the company is the strongest it has been in its 30-year history.”

Newsletter Subscription

Stay informed of the latest news and features